Literature DB >> 21854754

Prostate cancer increases hyaluronan in surrounding nonmalignant stroma, and this response is associated with tumor growth and an unfavorable outcome.

Andreas Josefsson1, Hani Adamo, Peter Hammarsten, Torvald Granfors, Pär Stattin, Lars Egevad, Anna Engström Laurent, Pernilla Wikström, Anders Bergh.   

Abstract

Our objective was to investigate whether the presence of a tumor increases hyaluronan (HA) levels in surrounding prostate tissues and whether this extratumoral HA influences tumor growth and outcome. From a series of 287 men diagnosed with prostate cancer at transurethral resection and followed up with watchful waiting, tissue microarrays were constructed, stained, and scored for HA. A high HA staining score in the tumor stroma or in nonmalignant prostate tissue stroma were both associated positively with higher Gleason score and larger tumor volume, and was associated with a poor outcome. HA staining score was not an independent marker for outcome (multivariate Cox, with Gleason score, tumor volume, stage, and HA variables). In an orthotopic rat prostate cancer model, hyaluronic acid synthase-1 mRNA levels and HA staining were increased in normal prostate tissue surrounding prostate cancer. Orthotopic prostate cancer growth was increased by intraprostatic injection of HA. In conclusion, cancer in the prostate apparently stimulates HA synthesis both in tumor stroma and in the surrounding normal tissue. This promoted tumor growth and was associated with an unfavorable outcome.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21854754      PMCID: PMC3181394          DOI: 10.1016/j.ajpath.2011.06.005

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  51 in total

1.  Lymph and blood vessel architecture in benign and malignant prostatic tissue: lack of lymphangiogenesis in prostate carcinoma assessed with novel lymphatic marker lymphatic vessel endothelial hyaluronan receptor (LYVE-1).

Authors:  Lutz Trojan; Maurice Stephan Michel; Florian Rensch; David G Jackson; Peter Alken; Rainer Grobholz
Journal:  J Urol       Date:  2004-07       Impact factor: 7.450

Review 2.  Tumor-host interactions: a far-reaching relationship.

Authors:  Sandra S McAllister; Robert A Weinberg
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

3.  Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment.

Authors:  Andreas Josefsson; Pernilla Wikström; Torvald Granfors; Lars Egevad; Lars Karlberg; Pär Stattin; Anders Bergh
Journal:  Eur Urol       Date:  2005-10       Impact factor: 20.096

Review 4.  Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer.

Authors:  I F Lissbrant; E Lissbrant; J E Damber; A Bergh
Journal:  Scand J Urol Nephrol       Date:  2001-12

5.  Pigment epithelium-derived factor stimulates tumor macrophage recruitment and is downregulated by the prostate tumor microenvironment.

Authors:  Sofia Halin; Stina Häggström Rudolfsson; Jennifer A Doll; Susan E Crawford; Pernilla Wikström; Anders Bergh
Journal:  Neoplasia       Date:  2010-04       Impact factor: 5.715

6.  Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy.

Authors:  Anna Johansson; Stina Rudolfsson; Peter Hammarsten; Sofia Halin; Kristian Pietras; Jonathan Jones; Pär Stattin; Lars Egevad; Torvald Granfors; Pernilla Wikström; Anders Bergh
Journal:  Am J Pathol       Date:  2010-07-08       Impact factor: 4.307

Review 7.  Hypoxia drives prostate tumour progression and impairs the effectiveness of therapy, but can also promote cell death and serve as a therapeutic target.

Authors:  Stina Häggström Rudolfsson; Anders Bergh
Journal:  Expert Opin Ther Targets       Date:  2009-02       Impact factor: 6.902

8.  Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer.

Authors:  J Timothy Posey; Mark S Soloway; Sinan Ekici; Mario Sofer; Francisco Civantos; Robert C Duncan; Vinata B Lokeshwar
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

9.  Androgen receptor regulates CD168 expression and signaling in prostate cancer.

Authors:  Shi-Lung Lin; Donald Chang; Angela Chiang; Shao-Yao Ying
Journal:  Carcinogenesis       Date:  2008-01-03       Impact factor: 4.944

Review 10.  Promise and challenge: Markers of prostate cancer detection, diagnosis and prognosis.

Authors:  D A Troyer; J Mubiru; R J Leach; S L Naylor
Journal:  Dis Markers       Date:  2004       Impact factor: 3.434

View more
  39 in total

Review 1.  Dissecting the role of hyaluronan synthases in the tumor microenvironment.

Authors:  Alberto Passi; Davide Vigetti; Simone Buraschi; Renato V Iozzo
Journal:  FEBS J       Date:  2019-04-22       Impact factor: 5.542

2.  Hyaluronidase-Expressing Salmonella Effectively Targets Tumor-Associated Hyaluronic Acid in Pancreatic Ductal Adenocarcinoma.

Authors:  Nancy D Ebelt; Edith Zuniga; Kevin B Passi; Lukas J Sobocinski; Edwin R Manuel
Journal:  Mol Cancer Ther       Date:  2019-11-06       Impact factor: 6.261

3.  Hyaluronic acid and hyaluronidase as possible novel urine biomarkers for the diagnosis of prostate cancer.

Authors:  Ioannis Skarmoutsos; Athanasios Skarmoutsos; Ioannis Katafigiotis; Elisavet Tataki; Athina Giagini; Ioannis Adamakis; Christos Alamanis; Mordechai Duvdevani; Nikolaos Sitaras; Constantinos Constantinides
Journal:  Med Oncol       Date:  2018-05-25       Impact factor: 3.064

4.  Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells.

Authors:  Manabu Tatokoro; Fumitaka Koga; Soichiro Yoshida; Satoru Kawakami; Yasuhisa Fujii; Len Neckers; Kazunori Kihara
Journal:  Int J Cancer       Date:  2011-11-10       Impact factor: 7.396

5.  Inhibition of Mammalian Glycoprotein YKL-40: IDENTIFICATION OF THE PHYSIOLOGICAL LIGAND.

Authors:  Abhishek A Kognole; Christina M Payne
Journal:  J Biol Chem       Date:  2017-01-04       Impact factor: 5.157

6.  Multilayered, Hyaluronic Acid-Based Hydrogel Formulations Suitable for Automated 3D High Throughput Drug Screening of Cancer-Stromal Cell Cocultures.

Authors:  Brian J Engel; Pamela E Constantinou; Lindsey K Sablatura; Nathaniel J Doty; Daniel D Carson; Mary C Farach-Carson; Daniel A Harrington; Thomas I Zarembinski
Journal:  Adv Healthc Mater       Date:  2015-06-09       Impact factor: 9.933

7.  Development and validation of H11B2C2 monoclonal antibody-reactive hyaluronic acid binding protein: overexpression of HABP during human tumor progression.

Authors:  Rajeev K Boregowda; Hitesh N Appaiah; Mortha Karunakumar; Shivanna Parameshwariah; Geetha Avadani; Sunila Sunila; Shibdas Banerjee
Journal:  Tumour Biol       Date:  2012-10-26

8.  3D porous chitosan-alginate scaffolds: a new matrix for studying prostate cancer cell-lymphocyte interactions in vitro.

Authors:  Stephen J Florczyk; Gang Liu; Forrest M Kievit; Allison M Lewis; Jennifer D Wu; Miqin Zhang
Journal:  Adv Healthc Mater       Date:  2012-07-06       Impact factor: 9.933

9.  Characterization of a Gene Expression Signature in Normal Rat Prostate Tissue Induced by the Presence of a Tumor Elsewhere in the Organ.

Authors:  Hanibal Hani Adamo; Sofia Halin Bergström; Anders Bergh
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

Review 10.  Roles of Proteoglycans and Glycosaminoglycans in Wound Healing and Fibrosis.

Authors:  Shibnath Ghatak; Edward V Maytin; Judith A Mack; Vincent C Hascall; Ilia Atanelishvili; Ricardo Moreno Rodriguez; Roger R Markwald; Suniti Misra
Journal:  Int J Cell Biol       Date:  2015-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.